High CXCR4 expression impairs rituximab response and the prognosis of R-CHOP-treated diffuse large B-cell lymphoma patients

Survival of diffuse large B-cell lymphoma (DLBCL) patients has improved by inclusion of rituximab. Refractory/recurrent disease caused by treatment resistance is, however, a major problem. Determinants of rituximab sensitivity are not fully understood, but effect of rituximab are enhanced by antagon...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Laursen, Maria Bach, Reinholdt, Linn, Schönherz, Anna Amanda, Due, Hanne, Jespersen, Ditte Starberg, Grubach, Lykke, Ettrup, Marianne Schmidt, Røge, Rasmus, Falgreen, Steffen, Sørensen, Suzette, Bødker, Julie Støve, Schmitz, Alexander, Johnsen, Hans E., Bøgsted, Martin, Dybkær, Karen
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2019
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6366826/
https://ncbi.nlm.nih.gov/pubmed/30774774
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.26588
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados